Juniper Pharma (JNP) Tops Q4 EPS by 43c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. MRVL
2. ZS
3. STZ
4. PENG
5. NVDA
6. SPY
7. MSFT
8. SKYD
9. LEVI
10. APLD

Go back to Juniper Pharma (JNP) Tops Q4 EPS by 43c

Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results

March 7, 2017 6:00 AM EST

BOSTON, March 7, 2017 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced financial results for the three- and twelve-month periods ended December 31, 2016. Recent highlights include:

Advanced lead formulations for three intravaginal ring ("IVR") candidates: JNP-0101 (oxybutynin IVR) for overactive bladder in women, JNP-0201 (estradiol + natural progesterone IVR) for symptoms of menopause, and JNP-0301 (natural progesterone IVR) for the prevention of preterm birth ("PTB") in women with a short cervical length at... More